Use of the 13-valent pneumococcal conjugate vaccine in children and adolescents aged 6 - 17 years.
INTRODUCTION: The introduction of pneumococcal conjugate vaccines into infant immunization schedules has successfully reduced the incidence of pneumococcal disease caused by vaccine serotypes. Disease incidence is low in healthy 6 - 17-year-old children and young people; however, there are a number...
| Prif Awduron: | , , |
|---|---|
| Fformat: | Journal article |
| Iaith: | English |
| Cyhoeddwyd: |
2013
|
| _version_ | 1826272008548122624 |
|---|---|
| author | Mitchell, R Trück, J Pollard, A |
| author_facet | Mitchell, R Trück, J Pollard, A |
| author_sort | Mitchell, R |
| collection | OXFORD |
| description | INTRODUCTION: The introduction of pneumococcal conjugate vaccines into infant immunization schedules has successfully reduced the incidence of pneumococcal disease caused by vaccine serotypes. Disease incidence is low in healthy 6 - 17-year-old children and young people; however, there are a number of clinical conditions that put individuals in this age group at increased risk. Expansion of the license of a 13-valent pneumococcal conjugate vaccine , PCV-13, to include the 6 - 17 age group has recently been approved by European and American regulatory bodies. AREAS COVERED: Studies assessing the safety, immunogenicity, and efficacy of pneumococcal conjugate vaccines in both healthy and high-risk 6 - 17-year-old children and adolescents are covered and the potential impact of PCV-13 in these populations is discussed. The use of the 23-valent pneumococcal polysaccharide vaccine, PPV-23, in high-risk children and adolescents is also considered. EXPERT OPINION: Expanding the use of PCV-13 to include high-risk children and adolescents aged 6 - 17 has the potential to prevent additional cases of disease; however, vaccination of this population may no longer be necessary when herd immunity to PCV-13 serotypes becomes fully established. Despite the broader serotype coverage of PPV-23, the benefits of this vaccine in high-risk populations are uncertain. |
| first_indexed | 2024-03-06T22:05:45Z |
| format | Journal article |
| id | oxford-uuid:50164cbc-5411-4b3e-a0fa-61c48e3d0ff0 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T22:05:45Z |
| publishDate | 2013 |
| record_format | dspace |
| spelling | oxford-uuid:50164cbc-5411-4b3e-a0fa-61c48e3d0ff02022-03-26T16:11:28ZUse of the 13-valent pneumococcal conjugate vaccine in children and adolescents aged 6 - 17 years.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:50164cbc-5411-4b3e-a0fa-61c48e3d0ff0EnglishSymplectic Elements at Oxford2013Mitchell, RTrück, JPollard, AINTRODUCTION: The introduction of pneumococcal conjugate vaccines into infant immunization schedules has successfully reduced the incidence of pneumococcal disease caused by vaccine serotypes. Disease incidence is low in healthy 6 - 17-year-old children and young people; however, there are a number of clinical conditions that put individuals in this age group at increased risk. Expansion of the license of a 13-valent pneumococcal conjugate vaccine , PCV-13, to include the 6 - 17 age group has recently been approved by European and American regulatory bodies. AREAS COVERED: Studies assessing the safety, immunogenicity, and efficacy of pneumococcal conjugate vaccines in both healthy and high-risk 6 - 17-year-old children and adolescents are covered and the potential impact of PCV-13 in these populations is discussed. The use of the 23-valent pneumococcal polysaccharide vaccine, PPV-23, in high-risk children and adolescents is also considered. EXPERT OPINION: Expanding the use of PCV-13 to include high-risk children and adolescents aged 6 - 17 has the potential to prevent additional cases of disease; however, vaccination of this population may no longer be necessary when herd immunity to PCV-13 serotypes becomes fully established. Despite the broader serotype coverage of PPV-23, the benefits of this vaccine in high-risk populations are uncertain. |
| spellingShingle | Mitchell, R Trück, J Pollard, A Use of the 13-valent pneumococcal conjugate vaccine in children and adolescents aged 6 - 17 years. |
| title | Use of the 13-valent pneumococcal conjugate vaccine in children and adolescents aged 6 - 17 years. |
| title_full | Use of the 13-valent pneumococcal conjugate vaccine in children and adolescents aged 6 - 17 years. |
| title_fullStr | Use of the 13-valent pneumococcal conjugate vaccine in children and adolescents aged 6 - 17 years. |
| title_full_unstemmed | Use of the 13-valent pneumococcal conjugate vaccine in children and adolescents aged 6 - 17 years. |
| title_short | Use of the 13-valent pneumococcal conjugate vaccine in children and adolescents aged 6 - 17 years. |
| title_sort | use of the 13 valent pneumococcal conjugate vaccine in children and adolescents aged 6 17 years |
| work_keys_str_mv | AT mitchellr useofthe13valentpneumococcalconjugatevaccineinchildrenandadolescentsaged617years AT truckj useofthe13valentpneumococcalconjugatevaccineinchildrenandadolescentsaged617years AT pollarda useofthe13valentpneumococcalconjugatevaccineinchildrenandadolescentsaged617years |